3.570EUR+2.18%Mkt Cap: 360.59M EURP/E: —Last update: 2026-05-14
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and g…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-2.27
PEG—
P/B7.01
P/S4.80
EV/EBITDA-10.79
EV/Revenue4.76
EPS (TTM)-0.58
EPS (Forward)-1.58
Cash Flow & Leverage
FCF Yield-14.85%
FCF Margin-71.30%
Operating CF-39.40M EUR
CapEx (TTM)3.53M EUR
Net Debt/EBITDA0.08
Net Debt-2.64M EUR
Technical
SMA 503.231 (+10.5%)
SMA 2003.288 (+8.6%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)357.01K
Avg Vol (10d)200.43K
Technical Indicators
RSI (14)58.3
MACD0.0475
MACD Signal0.0303
MACD Hist.+0.0172
BB Upper3.736 EUR
BB Middle3.397 EUR
BB Lower3.057 EUR
BB Width19.99%
ATR (14)0.2285 EUR
Vol Ratio (20d)1.84x
52W Range
1.23465% of range4.840
52W High4.840 EUR
52W Low1.234 EUR
Profitability
Gross Margin86.57%
EBITDA Margin-44.11%
Profit Margin-92.66%
Oper. Margin-333.43%
ROE-89.05%
ROA-20.82%
Revenue Growth-37.20%
Earnings Growth—
Balance Sheet
Debt/Equity1.20
Current Ratio1.52
Quick Ratio0.35
Book Value/Sh0.5111 EUR
Cash/Share0.3470 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.72.61M
Float64.64M
Insiders48.01%
Institutions8.74%
Analyst Consensus
Rating—
Target (Mean)6.500 EUR
Target Range6.500 EUR – 6.500 EUR
# Analysts1
Company
Market Cap360.59M EUR
Enterprise Value357.65M EUR
Revenue (TTM)75.11M EUR
Gross Profit63.15M EUR
Net Income (TTM)-67.59M EUR
Revenue/Share0.7480 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees224
Last Price3.570 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010425595